BR9915292A - Associação, utilização de riluzol e composição farmacêutica. - Google Patents

Associação, utilização de riluzol e composição farmacêutica.

Info

Publication number
BR9915292A
BR9915292A BR9915292-4A BR9915292A BR9915292A BR 9915292 A BR9915292 A BR 9915292A BR 9915292 A BR9915292 A BR 9915292A BR 9915292 A BR9915292 A BR 9915292A
Authority
BR
Brazil
Prior art keywords
riluzole
association
pharmaceutical composition
combination
riluzol
Prior art date
Application number
BR9915292-4A
Other languages
English (en)
Inventor
Michel Dib
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BR9915292A publication Critical patent/BR9915292A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • External Artificial Organs (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Cosmetics (AREA)

Abstract

"ASSOCIAçãO, UTILIZAçãO DE RILUZOL E COMPOSIçãO FARMACêUTICA". Associação de um alfa-tocoferol e de riluzol ou de um sal farmaceuticamente aceitável deste composto e utilização desta associação para o tratamento da esclerose lateral amiotrófica.
BR9915292-4A 1998-11-13 1999-11-09 Associação, utilização de riluzol e composição farmacêutica. BR9915292A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814250A FR2785808B1 (fr) 1998-11-13 1998-11-13 Association riluzole et alpha-tocopherol
PCT/FR1999/002753 WO2000028992A1 (fr) 1998-11-13 1999-11-09 Association riluzole et alpha-tocopherol

Publications (1)

Publication Number Publication Date
BR9915292A true BR9915292A (pt) 2001-08-07

Family

ID=9532674

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915292-4A BR9915292A (pt) 1998-11-13 1999-11-09 Associação, utilização de riluzol e composição farmacêutica.

Country Status (23)

Country Link
US (2) US6642262B2 (pt)
EP (1) EP1128829B1 (pt)
JP (1) JP4693241B2 (pt)
KR (1) KR100641472B1 (pt)
CN (1) CN1177587C (pt)
AT (1) ATE295168T1 (pt)
AU (1) AU776242B2 (pt)
BR (1) BR9915292A (pt)
CA (1) CA2350671C (pt)
CZ (1) CZ298808B6 (pt)
DE (1) DE69925301T2 (pt)
DK (1) DK1128829T3 (pt)
EA (1) EA003671B1 (pt)
ES (1) ES2239858T3 (pt)
FR (1) FR2785808B1 (pt)
HK (1) HK1041220B (pt)
HU (1) HU226067B1 (pt)
IL (1) IL142708A0 (pt)
NO (1) NO328349B1 (pt)
PT (1) PT1128829E (pt)
TR (1) TR200101346T2 (pt)
WO (1) WO2000028992A1 (pt)
ZA (1) ZA200103810B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
EP1938814A4 (en) * 2005-10-18 2009-06-03 Ono Pharmaceutical Co PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
US20070099156A1 (en) * 2005-10-28 2007-05-03 Jeff Wagner Self-etching dental primer compositions and methods and systems utilizing such compositions
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2014145776A2 (en) * 2013-03-15 2014-09-18 Baylor College Of Medicine Msp and its receptors in the therapy of amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5843641A (en) * 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
JP3889844B2 (ja) * 1997-02-10 2007-03-07 龍兒 梶 筋萎縮性側索硬化症治療剤
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique

Also Published As

Publication number Publication date
JP4693241B2 (ja) 2011-06-01
NO20012308L (no) 2001-05-10
ATE295168T1 (de) 2005-05-15
WO2000028992A1 (fr) 2000-05-25
FR2785808A1 (fr) 2000-05-19
CZ298808B6 (cs) 2008-02-06
ES2239858T3 (es) 2005-10-01
AU1165500A (en) 2000-06-05
HUP0105301A2 (hu) 2002-05-29
IL142708A0 (en) 2002-03-10
CA2350671A1 (fr) 2000-05-25
ZA200103810B (en) 2002-08-12
EA200100530A1 (ru) 2001-10-22
CZ20011561A3 (cs) 2001-08-15
CN1177587C (zh) 2004-12-01
US20030125363A1 (en) 2003-07-03
NO20012308D0 (no) 2001-05-10
HUP0105301A3 (en) 2006-07-28
AU776242B2 (en) 2004-09-02
KR20010080407A (ko) 2001-08-22
HU226067B1 (en) 2008-04-28
EP1128829A1 (fr) 2001-09-05
TR200101346T2 (tr) 2002-05-21
FR2785808B1 (fr) 2002-12-06
PT1128829E (pt) 2005-07-29
US6642262B2 (en) 2003-11-04
DE69925301D1 (de) 2005-06-16
US20020019426A1 (en) 2002-02-14
JP2002529506A (ja) 2002-09-10
EP1128829B1 (fr) 2005-05-11
DE69925301T2 (de) 2006-01-26
EA003671B1 (ru) 2003-08-28
CN1326348A (zh) 2001-12-12
DK1128829T3 (da) 2005-08-29
HK1041220A1 (en) 2002-07-05
NO328349B1 (no) 2010-02-01
HK1041220B (zh) 2005-07-22
KR100641472B1 (ko) 2006-10-31
CA2350671C (fr) 2010-05-04

Similar Documents

Publication Publication Date Title
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ATE336238T1 (de) Neue 4-dedimethylaminotetracyclinderivate
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BR9807234A (pt) Composição farmacêutica
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
IL139164A0 (en) Riluzole and levodopa combinations for treating parkinson's disease
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
BR9915292A (pt) Associação, utilização de riluzol e composição farmacêutica.
ES2194129T3 (es) Compuestos farmaceuticos.
WO2000002877A3 (en) New pharmaceutically active compounds
BR9907734A (pt) Emprego de preparados em pó contendo hidroxipiridona para o tratamento de tumores da perna e de pressão
FR2774290B1 (fr) Composition pharmaceutique pour l'administration par voie nasale de thiocolchicoside
DE69928685D1 (de) Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
BR9714382A (pt) 17alfa-diidroequilina para uso como um antioxidante médico
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
ES2185708T3 (es) Inhibicion de la biosintesis de leucotrienos con derivados de urea.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/428, A61K 31/355, A61P 25/28

Ipc: A61K 31/428 (2007.10), A61K 31/355 (2007.10), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTS 8O E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]